These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36721334)

  • 1. Multistate models as a framework for estimand specification in clinical trials of complex processes.
    Bühler A; Cook RJ; Lawless JF
    Stat Med; 2023 Apr; 42(9):1368-1397. PubMed ID: 36721334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study.
    Rehal S; Cro S; Phillips PP; Fielding K; Carpenter JR
    Clin Trials; 2023 Oct; 20(5):497-506. PubMed ID: 37277978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating estimands into clinical trial statistical analysis plans.
    Kang M; Kendall MA; Ribaudo H; Tierney C; Zheng L; Smeaton L; Lindsey JC
    Clin Trials; 2022 Jun; 19(3):285-291. PubMed ID: 35257600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework.
    Mitroiu M; Teerenstra S; Oude Rengerink K; Pétavy F; Roes KCB
    Pharm Stat; 2022 Sep; 21(5):1037-1057. PubMed ID: 35678545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translating questions to estimands in randomized clinical trials with intercurrent events.
    Stensrud MJ; Dukes O
    Stat Med; 2022 Jul; 41(16):3211-3228. PubMed ID: 35578779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
    Mitroiu M; Oude Rengerink K; Teerenstra S; Pétavy F; Roes KCB
    Trials; 2020 Jul; 21(1):671. PubMed ID: 32703247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.
    Fletcher C; Hefting N; Wright M; Bell J; Anzures-Cabrera J; Wright D; Lynggaard H; Schueler A
    Ther Innov Regul Sci; 2022 Jul; 56(4):637-650. PubMed ID: 35462609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-world intervention graphs for defining, identifying, and communicating estimands in clinical trials.
    Ocampo A; Bather JR
    Stat Med; 2023 Sep; 42(21):3892-3902. PubMed ID: 37340887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events.
    Bissonnette R; Eichenfield LF; Simpson E; Thaçi D; Kabashima K; Thyssen JP; Guttman-Yassky E; Nunes FP; Gamalo M; Ahmad F; Kuligowski M; Sun K; Pipper C; Christensen AW; D'Angelo P; Milutinovic M; Guettner A; Silverberg JI
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):976-983. PubMed ID: 36652273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of tripartite estimands using adherence causal estimators under the causal inference framework.
    Qu Y; Luo J; Ruberg SJ
    Pharm Stat; 2021 Jan; 20(1):55-67. PubMed ID: 33442928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines.
    Ratitch B; Goel N; Mallinckrodt C; Bell J; Bartlett JW; Molenberghs G; Singh P; Lipkovich I; O'Kelly M
    Ther Innov Regul Sci; 2020 Mar; 54(2):370-384. PubMed ID: 32072586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimands in published protocols of randomised trials: urgent improvement needed.
    Kahan BC; Morris TP; White IR; Carpenter J; Cro S
    Trials; 2021 Oct; 22(1):686. PubMed ID: 34627347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials.
    Jin M; Liu G
    Contemp Clin Trials; 2020 Sep; 96():106093. PubMed ID: 32777382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimands for factorial trials.
    Kahan BC; Morris TP; Goulão B; Carpenter J
    Stat Med; 2022 Sep; 41(22):4299-4310. PubMed ID: 35751568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining estimands using a mix of strategies to handle intercurrent events in clinical trials.
    Qu Y; Shurzinske L; Sethuraman S
    Pharm Stat; 2021 Mar; 20(2):314-323. PubMed ID: 33098267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimands for overall survival in clinical trials with treatment switching in oncology.
    Manitz J; Kan-Dobrosky N; Buchner H; Casadebaig ML; Degtyarev E; Dey J; Haddad V; Jie F; Martin E; Mo M; Rufibach K; Shentu Y; Stalbovskaya V; Sammi Tang R; Yung G; Zhou J
    Pharm Stat; 2022 Jan; 21(1):150-162. PubMed ID: 34605168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimands in hematologic oncology trials.
    Sun S; Weber HJ; Butler E; Rufibach K; Roychoudhury S
    Pharm Stat; 2021 Jul; 20(4):793-805. PubMed ID: 33686762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining estimands in clinical trials: A unified procedure.
    Han S; Zhou XH
    Stat Med; 2023 May; 42(12):1869-1887. PubMed ID: 36883638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic.
    Qu Y; Lipkovich I
    Ther Innov Regul Sci; 2021 Sep; 55(5):984-988. PubMed ID: 33983621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Handling Missing Data and Drop Out in Hospice/Palliative Care Trials Through the Estimand Framework.
    Grobler AC; Lee KJ; Wong A; Currow DC; Braat S
    J Pain Symptom Manage; 2022 Apr; 63(4):e431-e439. PubMed ID: 34954068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.